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Incorporation of dioleoyl ~-(monomethoxy polyethyleneglycol su~inyl)phosphotidylethanol~ine (PEG-PE) into large unilamellar liposomes 
composed of egg posphatidylcholine:cholesterol (1: 1) does not significantly increase tbe content leakage when the liposomes are exposed to 90% 
human serum at 37”C, yet the liposomes show a significant increase in the blood circulation half-life (t:=5 h) as compared to those without 
PEG-PE(tl< 30 min). The PEG-PE’s activity to prolong the circulation time of liposomes is &reater than that of the ganglioside GM,, a well- 
described glycolipid with this activity. Another ~phipat~c PEG derivative, PEG stearate, also prolongs the liposome circulation time, althou~ 
its activity is less than that of GM,. Amphipathic PEGS may be useful for the sustained release and the targeted rug delivery by liposomes. 
Liposome; Polyethyleneglycol; Drug delivery system 
1. INTRODUCTION 
Liposomes have been used as a drug delivery system 
in the last two decades [11. Most of the applications are 
based on the fact that liposomes are avidly taken up by 
the RES cells in liver and spleen [I ,2]. However, 
liposomal drug delivery to cells or tissues other than the 
RES has been very difficult. Recently, we have shown 
in a model system that optimal target binding and 
retention of the immunoliposomes can only be achieved 
with liposomes which show a relatively low rate of RES 
uptake 131. In these studies, ganglioside GM1 was used 
as a molecule which endows the liposomes with a lower 
level of RES uptake and hence a prolonged circulation 
half-life [3]. Allen and coworkers were the first to show 
this unusual activity of GM1 [4,5] and the name ‘stealth 
liposomes’ (‘stealth liposome’ is a registered trademark 
of Liposome Technology, Inc.) has been given to this 
new class of liposomes [6]. Gabizon and Papahad- 
jopoulos have further examined a number of other 
natural and synthetic lipids for the ‘stealth’ activity [7]. 
Importantly, they have shown that liposomes with a 
prolonged circulation time accumulate efficiently in a 
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solid tumor model system [7]. Since it has been shown 
that conjugation of PEG to proteins significantly pro- 
longs the circulation half-life of the protein [81, we have 
investigated if the lipophilic PEG derivatives can 
significantly prolong the circulation half-life of 
liposomes. 
2. MATERIALS AND METHODS 
2. I . Materials 
PEG-O% (A& = SOOO), DTPA cyclic anhydride, cholesterol, and 
calcein were purchased from Sigma. Ganglioside GM1 was purchased 
from Calbiochem. Triethylamine (>99% purity) was a product of 
Aldrich. Dioleoyl PE and egg yolk PC from Avanti Polar Lipids were 
used. Myrj 59 (polyethyleneglycol stearyl ester, M, = 4500) was from 
Serva. 14C-labeled ioleoyl PE was purchased from Amersham, 
“‘InCl3 (carrier-free) was from New England Nuclear. Synthesis of 
DTPA-SA is described elsewhere [9]. Pooled normal human serum 
was supplied by Scantibody, Inc. 
3.2. Synthesis of PEG-PE 
An aliquot of PEG-OSu in CHCl3 was added to a solution of PE 
in CHCl3, followed by addition of triethylamine (PEG- 
OSu/PE/triethylamine = 3 : 1: 3.5, m/m). When necessary, 
radiolabeled [14C]PE was added as a tracer. The reaction mixture was 
incubated overnight at room temperature and CHC13 was evaporated 
with a stream of nitrogen gas. Full conversion of the PE primary 
aminogroup was confirmed by the negative ninhydrin reactivity after 
the products were separated by thin layer chromatography. 
Phospholipid phosphorus assay [lo] showed the appearance of a new 
phosphate-positive spot at a higher Rr value than PE. The reaction 
mixture was redissolved in 0.145 M NaCl. &reacted PEG-OSu is 
rapidly hydrolyzed in the aqueous media. The resulting mixture in 
saline was applied to a Bio-Gel Al .5M column, preequilibrated with 
saline. Peak fractions containing PEG-PE micelles eluted in the void 
volume were pooled, dialyzed against water and lyophilized. 
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3.3. Liposome preparation 
Liposomes were prepared with PC and chol (1: 1 molar ratio). As 
a tracer marker illIn was used [ll], which was bound to DTPA-SA 
(1 mol% incorporated into the lipid bilayer). In some cases, 
7.4 mole/o of ganglioside GMi, Myrj 59 or PEG-PE was added to the 
lipid mixture. Each mixture of lipids in CHClr/EtOH was placed in 
a round-bottom glass tube and the organic solvent was evaporated 
with a stream of nitrogen gas. The lipid film was additionally vacuum 
desiccated for 2 h. Normal saline was added and the lipid was allow- 
ed to hydrate for 1 h. The lipid suspension was vortexed for 2 min, 
sonicated in a bath sonicator for 1 min and extruded 10 times 
through two stacked Nucleopore filters (0.4 and 0.2rm). When 
necessary, a 62 mM solution of calcein in 10 mM sodium phosphate 
buffer, pH 8, was used instead of the normal saline as the liposome 
aqueous phase. Liposome size was measured in a Coulter N4SD sub- 
micron particle analyzer (Coulter, Hialeah, FL). 
3.4. Liposome stability 
Non-entrapped fluorescent dye was removed by gel filtration on a 
Sephadex G-75 column. Liposome stability was measured as the 
quenching of the calcein fluorescence after incubation in phosphate- 
buffered saline or in the presence of 90% human serum at 37°C. 
Samples from the incubation mixture were diluted with phosphate- 
buffered saline and the fluorescence was measured in the presence 
and absence of 0.1% Triton X-100, using a Perkin-Elmer LS-5 
fluorescence spectrophotometer. The percent dye leakage was 
calculated as described earlier [12]. 
3 5. Biodistribution studies 
Biodistribution studies were performed on male Balb/c mice as 
described previously [l 11. Liposomes labeled with “iIn were injected 
in the tail vein (0.12-o. 14 mg PC per mouse). Weight of mouse blood 
was assumed to be 7.3% of the body weight. Data were expressed as 
percent of the injected dose accumulated per organ. Radioactivity ac- 
cumulated in lung, heart and kidneys did not exceed 3@/o f the in- 
jected dose. 
3. RESULTS AND DISCUSSION 
The conjugate of PEG with PE was purified by gel 
filtration on a Bio-Gel Al .5M column as micelles. Us- 
ing “C-labeled PE with known specific radioactivity 
and the dry weight of the purified PEG-PE, the molar 
ratio of PEG to PE in the conjugate was estimated to 
be 0.97 : 1, assuming that the molecular weight of PEG- 
OSu was 5000 Da as indicated by the manufacturer. 
Stable liposomes can be prepared from egg PC and chol 
(1: 1 molar ratio) incorporating up to 25 mol% PEG- 
PE and the fluorescent dye calcein can be entrapped in 
the liposomes. 
The stability of PEG-PE containing liposomes in 
human serum is shown in Fig. 1. Liposomes composed 
of egg PC/chol (1: 1, m/m) with or without 7.4 mol% 
PEG-PE were incubated at 37°C in phosphate-buffered 
saline or 90% normal human serum and the leakage of 
the entrapped calcein was measured over 12 h. It is 
clear from the data in Fig. 1 that PEG-PE did not in- 
crease the leakage rate of the liposomes incubated 
either in saline or in 90% serum. Only about 10% of 
the originally entrapped calcein had leaked in 12 h. 
Large unilamellar liposomes (d - 0.2 pm) of four 
different compositions were prepared for in vivo 
studies: egg PC/chol (1: 1, m/m), egg PC/chol/GMi 
(1: 1:0.16, m/m), egg PC/chol/Myrj 59 (1: 1:0.16, 
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Fig. 1. Calcein leakage from liposomes in serum or PBS. (m) 
Liposomes composed of PC/chol/PEG-PE (1: 1:0.16) in the 
presence of serum. (0) Liposomes composed of PC/chol/PEG-PE 
(1: 1: 0.16) in PBS. (A) Liposomes composed of PC/chol (1: 1) in the 
presence of serum. (A) Liposomes composed of PC/chol (1: 1) in 
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m/m) and egg PC/chol/PEG-PE (1: 1: 0.16, m/m). 
The liposomes were labeled with “‘In tracer bound to 
a lipophilic derivative of DTPA chelator which is incor- 
porated in the liposome membrane. The biodistribu- 
tions of the liposomes were studied in the mouse after 
i.v. injection (Fig. 2). Liposomes composed of egg PC 
and chol were very rapidly taken up by the RES (liver 
and spleen). By 5 h after injection, these liposomes had 
completely cleared from the blood and resided almost 
entirely in the liver and spleen. Liposomes of this size 
range and composition are readily taken up by the RES 
[2]. The activities of PEG-PE, Myrj 59 and GM1 in 
80 
60 
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Fig. 2. Blood clearance of liposomes after intravenous injection. (A) 
Radioactivity of lipid in blood. (B) Radioactivity of lipid in liver and 
spleen (combined). Data are expressed as mean f SE (n = 3). (m) 
Liposomes composed of PC/chol/PEG-PE (1: 1: 0.16). (+) 
Liposomes composed of PC/chol/GMr (1: 1:0.16). (x) Liposomes 
composed of PC/chol/Myrj 59 (1: 1: 0.16). (A) Liposomes composed 
of PC/chol (1: 1). 
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prolonging the circulation halflife of the liposomes can 
also be seen in Fig. 2. The activity of PEG-PE was 
striking. At 1 h after injection, 85% of the injected 
dose was found in the blood and only 18% in the liver 
and spleen. Even at 5 h, there were still more liposomes 
in the blood (49%) than in the RES (38Ve). Myrj 59 also 
showed some activity although it was not stronger than 
that of G&Ii. The estimated fr/t for liposome blood 
clearance is~30 min, 0.5 h, 1.5 h and 5 h for PC/chol 
liposomes and liposomes additionally cont~ning Myrj 
59, GMr and PEG-PE, respectively. Thus, both am- 
phipathic PEG significantly enhanced the blood 
residence time of the liposomes, although the activity 
of PEG-PE was superior to that of Myrj 59. 
Conjugation of PEG to proteins prolongs the cir- 
culation time of the protein [8,13]. Adsorption of PEG- 
containing polymers to polystyrene microspheres 
results in reduced RES uptake [ 14,151. There may be 
two mutually non-excluding factors which govern the 
affinity of liposomes to the RES: nonspecific 
hydrophobic interactions of liposomes with RES cells, 
and a specific opsonizatio~ reaction involving some 
blood component(s) 116-181. Coating a liposome sur- 
face with PEG may increase the hydrophilic& of the 
liposome surface such that the nonspecific interaction 
of liposomes with RES cells is reduced. Additionally, 
PEG may sterically prevent he coating of opsonins to 
the liposome, resulting in a reduced specific interaction 
with the RES cells. 
We have recently shown that the prolonged circula- 
tion time allows the immunoliposomes to bind with the 
target cells very effectively [3f. This is an important 
feature of using i~unoliposomes as a t~get-specific 
drug delivery vehicle. Our present data indicate that 
amphipathic PEG can significantly enhance the 
liposome concentration in the circulation at a given 
time. Its use in the Iiposome-mediated drug targeting 
should be seriously evaluated. 
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